- Medical news & Guidelines
- Cardiology and CTVS
- Critical Care
- Diabetes and Endocrinology
- Laboratory Medicine
- Health news
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Dadra and Nagar Haveli
- Daman and Diu
- Himachal Pradesh
- Jammu & Kashmir
- Madhya Pradesh
- Tamil Nadu
- Uttar Pradesh
- West Bengal
- Medical Education
Alkem gets CDSCO panel okay to manufacture, market Metformin, Sitagliptin FDC
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has granted permission to drug-maker Alkem for manufacturing and marketing the antidiabetic Fixed Dose Combination (FDC) drug consisting of Metformin Hydrochloride and Sitagliptin Phosphate.This came in line with the proposal presented by the firm for the antidiabetic FDC...
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has granted permission to drug-maker Alkem for manufacturing and marketing the antidiabetic Fixed Dose Combination (FDC) drug consisting of Metformin Hydrochloride and Sitagliptin Phosphate.
This came in line with the proposal presented by the firm for the antidiabetic FDC of Metformin Hydrochloride as an extended release form and Sitagliptin Phosphate along with bioequivalence (BE) study results before the committee.
Metformin is a popular antihyperglycemic agent that belongs to the biguanide class of drugs. Currently, metformin is the drug of choice for the management of type II diabetes. It lowers blood glucose levels by decreasing hepatic glucose production (gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization. Metformin is the drug of choice for obese type II diabetes patients.
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used for the management of type 2 diabetes mellitus. Sitagliptin inhibits DPP-4, which leads to increased levels of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), decreased levels of glucagon, and a stronger insulin response to glucose.
Earlier, at the 87th SEC meeting for Endocrinology & Metabolism held on June 15, 2021 and June 16, 2021 at CDSCO, the drug-maker Alkem presented the BE protocol before the committee and requested manufacturing and marketing approval based on the BE study.
In response, the committee then noted that the proposal was already approved in combi-kit form and that FDC was also approved in various other strengths.
Therefore, at the earlier meeting the firm was granted permission to conduct a BE study, and in addition to this, the firm was directed that the results of the study should be presented before the committee for further consideration.
At the latest SEC meeting, the committee thoroughly examined the proposal of Alkem and the BE study results of the said combination antidiabetic drug. After detailed deliberation, the committee recommended the manufacturing and marketing of the proposed FDC.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at email@example.com.